The Hutchinson Institute for Cancer Outcomes Research (HICOR) has named Gary Lyman, MD, MPH, the Institute’s Co-Director with Scott Ramsey, MD, PhD, an internist and health-care economist, and a member of the Cancer Prevention Program in the Public Health Sciences Division at Fred Hutchinson Cancer Research Institute. Dr. Lyman comes to HICOR having previously served as Professor of Medicine and Senior Fellow at the Duke Center for Clinical Health Policy Research and Director of the Comparative Effectiveness and Outcomes Research Program in Oncology at the Duke Cancer Institute.
HICOR is a research institute based at Fred Hutchinson Cancer Research Center that is charged with evaluating and improving the effectiveness and value of cancer prevention and treatment strategies through collaborative research. Dr. Lyman started in this new position on January 2, 2014.
The HICOR Team
Dr. Lyman is recognized for his leadership in comparative effectiveness and health services and outcomes research. Co-Director Dr. Ramsey said “We are privileged to have Dr. Lyman on the HICOR
team. Gary’s wealth of oncology expertise, his strong clinical and health outcomes research portfolio, and his leadership in developing and increasing adherence to oncology clinical practice guidelines will be a significant asset to HICOR’s commitment to reducing cost, while improving the quality of cancer care for insurers, providers, and patients.”
Dr. Lyman will hold appointments within the Cancer Prevention Program at the Hutchinson Research Center, the Division of Medical Oncology at the University of Washington School of Medicine, and affiliate appointments within the Department of Health Services at the University of Washington School of Public Health and in the School of Pharmacy. Dr. Lyman also will practice as a medical oncologist in the Breast Cancer Program at Seattle Cancer Care Alliance.
Dr. Lyman said, “I was particularly drawn to HICOR’s focus on how cancer treatment affects the entire patient, from the medical to the financial. The work that HICOR is doing will undoubtedly have a dramatic impact on improving the practice of oncology in the future. I am proud to be a part of this groundbreaking opportunity.” ■
